Navigation Links
Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement

FORT LAUDERDALE, Fla., April 24, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals, soon to be changed from Hybrid Fuels, Inc., (Pink Sheets: HRID) announced today that it has contracted with an FDA-approved manufacturer to begin production of the first supplement in its New Life Naturals™ product line.

The new supplement – New Life Naturals: For Her Senses™ – is an all-natural product intended to help the nearly 48% of American women suffering with female sexual dysfunction (FSD). Nouveau Life Pharmaceuticals began work on the supplement's formulation in February of this year and finalized the formula ahead of schedule. 

In order to minimize time-to-market and begin production immediately, Nouveau Life opted to partner with an FDA-approved manufacturing facility based in the U.S. The facility is a cGMP (current good manufacturing practice) compliant facility and meets all FDA requirements to manufacture food supplements and over the counter pharmaceuticals.

Nouveau Life expects production of the For Her Senses™ supplement to begin in the coming days and anticipates the nutraceutical will be available for sale to the public within two weeks.

About Hybrid Fuels, Inc.
The company was incorporated in the state of Nevada in 1998 as Polo Equities.  It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies. 

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Hybrid Fuels, Inc. undertakes no obligation to update such statements.


Nouveau Life Pharmaceuticals, Inc. - 954-903-2993

SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Clinical Development Plans for ISIS-APOCIIIRx
4. Research Alert -- Empire Asset Management Co. Initiates Coverage on Pacira Pharmaceuticals Inc. (NASDAQ: PCRX)
5. Avion Pharmaceuticals, LLC Names Michael Sullivan as new VP, Sales and Marketing
6. Valeant Pharmaceuticals to Announce 2012 First Quarter Results on May 3, 2012
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
8. Duane Morris Litigators Vincent Capuano, Anthony Fitzpatrick and Laura Vogel to Speak at American Conference Institutes Conference on Generic Pharmaceuticals
9. Qualitest Pharmaceuticals Receives FDA Approval for Levetiracetam Oral Solution, 100 mg/mL
10. MAP Pharmaceuticals Provides Update on LEVADEX® Program
11. Gamma Pharmaceuticals, Inc. Announces Distribution Agreement for New York Tri-state Area and Purchase Order for Gamma Energy GEL™
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... ScanWise Implant, the industry,s first MRI guided user interface ... scanning of patients with MR Conditional implants, such as ... the 2015 Radiological Society of North America Annual ... exams and supports diagnostic confidence of this growing patient ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... December 01, 2015 , ... ... Colon as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting 850,000 members ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting 850,000 members and over 200 operating ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Until now, ... criteria set forth in the MOMS (Management of Myelomeningocele Study) trial. One of these ... Control and Prevention), a BMI of 18.5 to 24.9 is considered normal, 25 - ...
(Date:11/30/2015)... ... 2015 , ... Stress, anxiety, illness, infection or even a need for eyeglasses ... Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in Hollywood, ... tumors. , “Bad headaches that don’t go away, that don’t have any ...
Breaking Medicine News(10 mins):